Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0HPWY)

• Drug Name: biochanin A Drug Info
• Synonyms: Biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether; 4'-methylgenistein; BIOCHANIN

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5280373
  ChEBI ID: CHEBI:17574
  CAS Number: CAS 491-80-5
  TTD Drug ID: DM0HPWY

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[4]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[4]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[4]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[4]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[11]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[12]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[13]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[13]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[14]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[15]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[16]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[2]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[17]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[18]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[2]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[274]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[275]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[276]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[276]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[33]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[277]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[278]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[279]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[276]

Drug(s) Targeting Fatty acid synthase (FASN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[19]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[4]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[20]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[21]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[22]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[22]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[4]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[4]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[4]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Estrogen-related receptor-beta (ESRRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[3]
DY131	DMFJ3VC	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Estrogen-related receptor-gamma (ESRRG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[3]
DY131	DMFJ3VC	Discovery agent	N.A.	Investigative	[24]
GSK4716	DMHUMP9	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Estrogen-related receptor-alpha (ESRRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rimexolone	DMTAREC	Arthritis	FA20	Approved	[25]
Pregnenolone	DM6VFO1	Schizophrenia	6A20	Phase 4	[26]
D-5519	DM9FAJM	Asthma	CA23	Phase 3	[27]
Dexamethasone palmitate	DMCMT4V	Choroidal neovascularization	9B76	Phase 1/2	[28]
RPR-106541	DMRGC5B	Asthma	CA23	Discontinued in Phase 2	[29]
Rofleponide	DM6OSPQ	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[30]
AD-121	DMB8XJM	Rheumatoid arthritis	FA20	Discontinued in Phase 1/2	[25]
GW-250495	DMWJZAP	Asthma	CA23	Discontinued in Phase 1	[25]
PLD-177	DMPHUBO	Allergic rhinitis	CA08.0	Terminated	[25]
Steroid hormone conjugates	DMOJM08	Cachexia	MG20	Terminated	[31]

Drug(s) Affected By Steroid hormone receptor ERR1 (ESRRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[32]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[34]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[36]
Bortezomib	DMNO38U	Leukemia		Approved	[37]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[38]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[39]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[40]

Drug(s) Affected By Metallothionein-2 (MT2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[41]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[44]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[45]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[47]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[48]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[49]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[50]

Drug(s) Affected By Agrin (AGRN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[50]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[50]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[54]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[55]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[56]

Drug(s) Affected By Low-density lipoprotein receptor class A domain-containing protein 4 (LDLRAD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[60]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[54]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[62]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 21 (TNFRSF21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[63]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[68]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[70]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[50]

Drug(s) Affected By Glutathione peroxidase 1 (GPX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Amlexanox	DM0DQM5	Respiratory tract inflammation	CA07	Approved	[73]
Selenium	DM25CGV	N. A.	N. A.	Approved	[74]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[75]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[76]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[79]

Drug(s) Affected By Guanine nucleotide-binding protein G(i) subunit alpha-3 (GNAI3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[80]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Bortezomib	DMNO38U	Leukemia		Approved	[37]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[83]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[85]

Drug(s) Affected By Folate receptor alpha (FOLR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[87]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[88]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[89]
Bortezomib	DMNO38U	Leukemia		Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[91]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[92]

Drug(s) Affected By Ganglioside GM2 activator (GM2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[93]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[95]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[97]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[98]

Drug(s) Affected By Cadherin-2 (CDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[102]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[103]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[104]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[105]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[106]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[107]

Drug(s) Affected By rRNA 2'-O-methyltransferase fibrillarin (FBL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[108]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[108]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[108]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[110]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[111]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[112]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[113]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[114]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[115]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[116]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[117]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[118]

Drug(s) Affected By Epidermal growth factor receptor substrate 15 (EPS15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[120]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[122]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[123]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[124]

Drug(s) Affected By Alpha-aminoadipic semialdehyde dehydrogenase (ALDH7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[126]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[127]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[128]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]

Drug(s) Affected By Eukaryotic translation initiation factor 5 (EIF5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[130]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[131]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[132]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]

Drug(s) Affected By Solute carrier family 25 member 3 (SLC25A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[86]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[124]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[133]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[134]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[135]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[136]

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[137]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[138]
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[139]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[140]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[141]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[144]

Drug(s) Affected By Serine/arginine-rich splicing factor 1 (SRSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[129]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[145]
Bortezomib	DMNO38U	Leukemia		Approved	[37]

Drug(s) Affected By AT-rich interactive domain-containing protein 5B (ARID5B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[102]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[146]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[145]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Indomethacin	DMSC4A7	Bursitis		Approved	[147]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[148]

Drug(s) Affected By Non-POU domain-containing octamer-binding protein (NONO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[149]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[124]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[130]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[150]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[151]

Drug(s) Affected By NADH dehydrogenase 1 alpha subcomplex subunit 5 (NDUFA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[152]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[153]
Fenretinide	DMRD5SP	Macular degeneration	9B78.3	Phase 3	[154]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[155]

Drug(s) Affected By Rab-like protein 6 (RABL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[156]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[157]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[122]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[130]
MG-132	DMKA2YS	N. A.	N. A.	Preclinical	[158]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[130]

Drug(s) Affected By Telomere-associated protein RIF1 (RIF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[159]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[60]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[161]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[162]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[163]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[164]

Drug(s) Affected By Mitochondrial mRNA pseudouridine synthase RPUSD3 (RPUSD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[165]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[156]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[164]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[166]

Drug(s) Affected By Sushi domain-containing protein 6 (SUSD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[121]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[167]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[86]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]

Drug(s) Affected By Prefoldin subunit 5 (PFDN5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[168]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[169]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[170]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[171]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[156]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[162]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[84]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[51]

Drug(s) Affected By Endophilin-A2 (SH3GL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[172]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[173]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[130]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[150]

Drug(s) Affected By Latexin (LXN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[176]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[176]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[177]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[56]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[174]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[174]

Drug(s) Affected By BRISC and BRCA1-A complex member 2 (BABAM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[61]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[178]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[161]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[179]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[51]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[181]

Drug(s) Affected By Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 (ENPP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[175]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[182]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[183]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[162]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[157]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[157]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[184]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[124]

Drug(s) Affected By Deoxyribose-phosphate aldolase (DERA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[58]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[72]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[185]

Drug(s) Affected By 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[187]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[82]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[188]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[189]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[190]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[191]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[192]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[193]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[194]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[195]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[196]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[197]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[198]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[199]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[200]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[201]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[201]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[201]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[202]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[203]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[204]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[205]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[206]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[207]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[208]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[209]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[210]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[211]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[212]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[202]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[213]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[211]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[214]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[212]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[211]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[216]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[217]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[218]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[219]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[220]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[221]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[57]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[222]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[223]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[193]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[224]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[225]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[226]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[227]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[228]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[229]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[230]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[231]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[232]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[233]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[234]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[235]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[236]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[237]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[238]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[239]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[235]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[240]

Drug(s) Affected By Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[241]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[242]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[243]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[244]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[245]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[246]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[247]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[248]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[249]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]

Drug(s) Affected By 72 kDa type IV collagenase (MMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[250]
Selenium	DM25CGV	N. A.	N. A.	Approved	[251]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[254]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[255]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[256]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[257]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[258]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[259]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[260]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[261]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[262]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[263]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[117]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[263]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[264]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[265]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[266]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[267]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[268]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[269]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[270]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[208]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[42]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[271]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[272]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[273]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[138]

Drug(s) Affected By Creatine kinase B-type (CKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[86]
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[280]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[280]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[281]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[282]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]

Drug(s) Affected By Matrix metalloproteinase-9 (MMP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[283]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[284]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[285]
Selenium	DM25CGV	N. A.	N. A.	Approved	[251]
Pentosan Polysulfate	DM2HRKE	Interstitial cystitis	GC00.3	Approved	[286]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[264]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[287]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[288]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[289]

Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[290]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[291]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[292]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[293]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[294]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[295]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[296]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[297]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[298]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[298]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[299]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[300]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[301]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[302]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[303]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[304]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[305]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[306]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[307]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[308]

Drug(s) Affected By Matrix metalloproteinase-14 (MMP14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[251]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[102]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[52]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[53]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[309]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[177]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[310]
Cysteamine	DMSYFM8	Nephropathic cystinosis	5C60	Approved	[311]

Drug(s) Affected By Urokinase plasminogen activator surface receptor (PLAUR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[312]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[313]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[314]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[315]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[316]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[317]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[176]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[107]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[176]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[65]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[318]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[319]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[262]
Selenium	DM25CGV	N. A.	N. A.	Approved	[51]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[320]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[321]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[322]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[323]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]

Drug(s) Affected By Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[215]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[324]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[325]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[326]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[327]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[328]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[329]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[330]
Mestranol	DMG3F94	Contraception	QA21	Approved	[331]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[332]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[333]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[334]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[335]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[336]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[337]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[338]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[339]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[339]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[340]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[341]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[2]
Estrogen-related receptor-alpha (ESRRA)	TTPNQAC	ERR1_HUMAN	Agonist	[3]
Estrogen-related receptor-beta (ESRRB)	TTKF0XS	ERR2_HUMAN	Agonist	[3]
Estrogen-related receptor-gamma (ESRRG)	TT9ZRHB	ERR3_HUMAN	Agonist	[3]
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[4]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)	TTHPFTS	Q965D7_PLAFA	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (CYP27B1)	OTTK98BH	CP27B_HUMAN	Gene/Protein Processing	[5]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[6]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Gene/Protein Processing	[7]
Alpha-aminoadipic semialdehyde dehydrogenase (ALDH7A1)	OTV57BZD	AL7A1_HUMAN	Gene/Protein Processing	[7]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[8]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[9]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[10]
AT-rich interactive domain-containing protein 5B (ARID5B)	OTUQ4CQY	ARI5B_HUMAN	Gene/Protein Processing	[7]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[8]
BRISC and BRCA1-A complex member 2 (BABAM2)	OTOY7FNT	BABA2_HUMAN	Gene/Protein Processing	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2829).
• [2] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [3] Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91.
• [4] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [5] 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005 Apr 5;111(13):1666-71.
• [6] Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J Neurooncol. 2006 Sep;79(2):135-42. doi: 10.1007/s11060-006-9126-0. Epub 2006 Apr 6.
• [7] Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate. 2002 Aug 1;52(3):201-12.
• [8] Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr Cancer. 2003;45(1):113-23. doi: 10.1207/S15327914NC4501_13.
• [9] Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol. 2006 Nov;101(4-5):216-25. doi: 10.1016/j.jsbmb.2006.06.021. Epub 2006 Sep 11.
• [10] Red clover aryl hydrocarbon receptor (AhR) and estrogen receptor (ER) agonists enhance genotoxic estrogen metabolism. Chem Res Toxicol. 2017 Nov 20;30(11):2084-2092.
• [11] 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
• [12] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [13] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [14] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [15] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [16] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [17] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [19] Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
• [20] Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
• [21] Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
• [22] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [23] Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1311-3.
• [24] Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem. 2005 May 5;48(9):3107-9.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
• [26] Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199)
• [28] Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8.
• [29] Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther. 1999 Aug;290(2):594-602.
• [30] Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60.
• [31] The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32.
• [32] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [33] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [34] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [35] Plasmatic concentration of organochlorine lindane acts as metabolic disruptors in HepG2 liver cell line by inducing mitochondrial disorder. Toxicol Appl Pharmacol. 2013 Oct 15;272(2):325-34.
• [36] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [37] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [38] Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells. Mol Endocrinol. 2010 Jun;24(6):1175-86.
• [39] [Regulation of orphan receptor ERR alpha by estrogen and progesterone in endometrial carcinoma cell line]. Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Jun 18;37(3):281-3.
• [40] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [41] Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma. Anticancer Res. 2003 Jan-Feb;23(1A):299-303.
• [42] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [43] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [44] Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
• [45] Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett. 1999 Nov 15;146(2):161-7.
• [46] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [47] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [48] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [49] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [50] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [51] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [52] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [53] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [54] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [55] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [56] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [57] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [58] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [59] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [60] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [61] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [62] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [63] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [64] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [65] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [66] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [67] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [68] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [69] Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001 Nov 29;20(55):7965-75. doi: 10.1038/sj.onc.1204985.
• [70] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [71] Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010 Oct;137(1):23-39.
• [72] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [73] Premature termination codon readthrough in human cells occurs in novel cytoplasmic foci and requires UPF proteins. J Cell Sci. 2017 Sep 15;130(18):3009-3022. doi: 10.1242/jcs.198176. Epub 2017 Jul 25.
• [74] Effects of Se-depletion on glutathione peroxidase and selenoprotein W gene expression in the colon. FEBS Lett. 2005 Jan 31;579(3):792-6. doi: 10.1016/j.febslet.2004.12.042.
• [75] Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism. PLoS One. 2014 Oct 20;9(10):e107299. doi: 10.1371/journal.pone.0107299. eCollection 2014.
• [76] A high-throughput reporter gene assay to prove the ability of natural compounds to modulate glutathione peroxidase, superoxide dismutase and catalase gene promoters in V79 cells. Free Radic Res. 2008 Aug;42(8):746-53.
• [77] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [78] Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol Sin. 2006 Aug;27(8):1078-84.
• [79] Involvement of oxidative stress in the impairment in biliary secretory function induced by intraperitoneal administration of aluminum to rats. Biol Trace Elem Res. 2007 Jun;116(3):329-48.
• [80] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [81] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [82] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [83] High levels of caveolar cholesterol inhibit progesterone-induced genomic actions in human and guinea pig gallbladder muscle. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G948-54. doi: 10.1152/ajpgi.90699.2008. Epub 2009 Feb 12.
• [84] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [85] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [86] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [87] Acute and chronic effects of some dietary bioactive compounds on folic acid uptake and on the expression of folic acid transporters by the human trophoblast cell line BeWo. J Nutr Biochem. 2008 Feb;19(2):91-100. doi: 10.1016/j.jnutbio.2007.01.007. Epub 2007 May 24.
• [88] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [89] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [90] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [91] Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006 Mar 1;66(5):2765-77.
• [92] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [93] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [94] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [95] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [96] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [97] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [98] Characterizing the genetic basis for nicotine induced cancer development: a transcriptome sequencing study. PLoS One. 2013 Jun 18;8(6):e67252.
• [99] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [100] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [101] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [102] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [103] Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2. Biochem Biophys Res Commun. 2019 Jun 11;513(4):834-840. doi: 10.1016/j.bbrc.2019.04.081. Epub 2019 Apr 16.
• [104] Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
• [105] ?9-tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer. Oncol Lett. 2018 Jun;15(6):8527-8535. doi: 10.3892/ol.2018.8407. Epub 2018 Apr 2.
• [106] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [107] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [108] Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
• [109] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [110] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [111] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [112] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [113] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [114] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [115] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [116] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [117] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [118] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [119] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [120] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [121] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [122] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [123] Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002 Mar 1;70(15):1821-39.
• [124] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [125] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [126] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [127] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [128] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [129] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [130] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [131] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [132] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [133] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [134] Alteration of estrogen-regulated gene expression in human cells induced by the agricultural and horticultural herbicide glyphosate. Hum Exp Toxicol. 2007 Sep;26(9):747-52. doi: 10.1177/0960327107083453.
• [135] Lipid Rafts Disruption Increases Ochratoxin A Cytotoxicity to Hepatocytes. J Biochem Mol Toxicol. 2016 Feb;30(2):71-9. doi: 10.1002/jbt.21738. Epub 2015 Aug 25.
• [136] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [137] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [138] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [139] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [140] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [141] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [142] Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
• [143] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [144] Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.
• [145] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [146] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [147] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [148] Inorganic arsenic as an endocrine disruptor: modulation of the glucocorticoid receptor pathway in placental cells via CpG methylation. Chem Res Toxicol. 2019 Mar 18;32(3):493-499.
• [149] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [150] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [151] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [152] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [153] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [154] 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.
• [155] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [156] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [157] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [158] Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity. J Biol Chem. 2020 Jan 31;295(5):1271-1287. doi: 10.1074/jbc.RA119.011174. Epub 2019 Dec 5.
• [159] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [160] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [161] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [162] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [163] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [164] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [165] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [166] Exposure to environmental bisphenol A inhibits HTR-8/SVneo cell migration and invasion. J Biomed Res. 2020 Jun 30;34(5):369-378. doi: 10.7555/JBR.34.20200013.
• [167] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [168] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [169] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [170] DNA microarray analysis of changes in gene expression induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 cells. Biomed Res. 2006 Jun;27(3):99-109. doi: 10.2220/biomedres.27.99.
• [171] The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol In Vitro. 2001 Aug-Oct;15(4-5):399-405. doi: 10.1016/s0887-2333(01)00043-1.
• [172] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [173] MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-B signaling. Toxicol Appl Pharmacol. 2021 Jun 1;420:115522. doi: 10.1016/j.taap.2021.115522. Epub 2021 Apr 8.
• [174] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [175] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [176] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [177] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [178] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [179] Gene alterations of ovarian cancer cells expressing estrogen receptors by estrogen and bisphenol a using microarray analysis. Lab Anim Res. 2011 Jun;27(2):99-107. doi: 10.5625/lar.2011.27.2.99. Epub 2011 Jun 22.
• [180] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [181] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [182] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [183] Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin. J Neurochem. 2004 Mar;88(5):1211-9. doi: 10.1046/j.1471-4159.2003.02247.x.
• [184] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [185] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [186] Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J Bone Miner Res. 2011 May;26(5):1145-53.
• [187] Down-regulation by nuclear factor kappaB of human 25-hydroxyvitamin D3 1alpha-hydroxylase promoter. Mol Endocrinol. 2004 Oct;18(10):2440-50. doi: 10.1210/me.2002-0441. Epub 2004 Jul 8.
• [188] Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage. J Biol Chem. 2007 Oct 12;282(41):29847-54.
• [189] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [190] Association of Arsenic Exposure with Whole Blood DNA Methylation: An Epigenome-Wide Study of Bangladeshi Adults. Environ Health Perspect. 2019 May;127(5):57011. doi: 10.1289/EHP3849. Epub 2019 May 28.
• [191] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [192] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [193] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [194] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [195] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [196] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [197] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [198] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [199] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [200] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [201] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [202] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [203] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [204] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [205] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [206] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [207] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [208] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [209] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [210] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [211] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [212] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [213] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [214] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [215] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [216] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [217] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [218] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [219] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [220] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [221] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [222] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [223] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [224] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [225] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [226] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [227] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [228] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [229] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [230] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [231] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [232] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [233] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [234] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [235] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [236] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [237] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [238] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [239] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [240] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [241] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [242] Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10-13):891-905. doi: 10.1016/j.steroids.2003.08.008.
• [243] Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol. 2000 Nov;17(5):991-1000. doi: 10.3892/ijo.17.5.991.
• [244] Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005 Jun 23;24(27):4388-400. doi: 10.1038/sj.onc.1208623.
• [245] Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840-5. doi: 10.1016/j.steroids.2005.04.010.
• [246] Expression of estrogen-, progesterone-, and androgen-responsive genes in MCF-7 and MDA-MB-231 cells treated with o,p'-DDT, p,p'-DDT, or endosulfan. J Biochem Mol Toxicol. 2021 Jun;35(6):1-8. doi: 10.1002/jbt.22773. Epub 2021 Mar 16.
• [247] Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
• [248] A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
• [249] Serum free BG-1 cell proliferation assay: a sensitive method for determining organochlorine pesticide estrogen receptor activation at the nanomolar range. Toxicol In Vitro. 2006 Apr;20(3):382-94. doi: 10.1016/j.tiv.2005.08.016. Epub 2005 Oct 19.
• [250] Oxidative Stress-Protective and Anti-Melanogenic Effects of Loliolide and Ethanol Extract from Fresh Water Green Algae, Prasiola japonica. Int J Mol Sci. 2018 Sep 18;19(9):2825. doi: 10.3390/ijms19092825.
• [251] Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
• [252] Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod. 2007 Apr;22(4):1161-7. doi: 10.1093/humrep/del464. Epub 2006 Dec 11.
• [253] Quercetin Suppresses the Migration and Invasion in Human Colon Cancer Caco-2 Cells Through Regulating Toll-like Receptor 4/Nuclear Factor-kappa B Pathway. Pharmacogn Mag. 2016 May;12(Suppl 2):S237-44. doi: 10.4103/0973-1296.182154. Epub 2016 May 11.
• [254] Troglitazone but not conjugated linoleic acid reduces gene expression and activity of matrix-metalloproteinases-2 and -9 in PMA-differentiated THP-1 macrophages. J Nutr Biochem. 2008 Sep;19(9):594-603. doi: 10.1016/j.jnutbio.2007.08.003. Epub 2007 Dec 21.
• [255] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [256] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [257] Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
• [258] Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
• [259] Repetitive nonlethal oxidant injury to retinal pigment epithelium decreased extracellular matrix turnover in vitro and induced sub-RPE deposits in vivo. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):4098-112. doi: 10.1167/iovs.05-1230.
• [260] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [261] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [262] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [263] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [264] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [265] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [266] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [267] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [268] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [269] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [270] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [271] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [272] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [273] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [274] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [275] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [276] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [277] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [278] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [279] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [280] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [281] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [282] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [283] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [284] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [285] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [286] Pentosan polysulfate decreases proliferation and extracellular matrix deposition by vascular smooth muscle cells isolated from failed hemodialysis access grafts. Clin Nephrol. 2000 Aug;54(2):121-7.
• [287] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [288] Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One. 2014 Jun 23;9(6):e99993. doi: 10.1371/journal.pone.0099993. eCollection 2014.
• [289] Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci. 2004 Apr;94(4):403-9. doi: 10.1254/jphs.94.403.
• [290] Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
• [291] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [292] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [293] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [294] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [295] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [296] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [297] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [298] Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
• [299] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [300] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [301] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [302] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [303] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [304] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [305] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [306] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [307] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [308] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [309] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [310] Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
• [311] Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS One. 2012;7(4):e34437. doi: 10.1371/journal.pone.0034437. Epub 2012 Apr 20.
• [312] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [313] Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells. Toxicol Appl Pharmacol. 2012 Mar 1;259(2):248-56. doi: 10.1016/j.taap.2012.01.002. Epub 2012 Jan 9.
• [314] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [315] [Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2009 Mar;30(3):145-9.
• [316] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [317] Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1. Biochem Biophys Res Commun. 2006 Sep 22;348(2):618-27. doi: 10.1016/j.bbrc.2006.07.098. Epub 2006 Jul 28.
• [318] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [319] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [320] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [321] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [322] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [323] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [324] Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
• [325] Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. Environ Toxicol. 2020 Nov;35(11):1179-1193. doi: 10.1002/tox.22983. Epub 2020 Jun 12.
• [326] Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001 Sep 14;166(1-2):79-89. doi: 10.1016/s0300-483x(01)00437-1.
• [327] Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J. 2006 Jul;20(9):1552-4. doi: 10.1096/fj.05-5413fje. Epub 2006 May 23.
• [328] Comparison of relative binding affinities to fish and mammalian estrogen receptors: the regulatory implications. Toxicol Lett. 2010 Feb 15;192(3):298-315. doi: 10.1016/j.toxlet.2009.11.004. Epub 2009 Nov 12.
• [329] Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect. 2004 Apr;112(5):524-31. doi: 10.1289/ehp.6649.
• [330] Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner. Reprod Toxicol. 2013 Dec;42:49-57. doi: 10.1016/j.reprotox.2013.07.019. Epub 2013 Jul 26.
• [331] Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci Biotechnol Biochem. 2002 Jul;66(7):1479-87. doi: 10.1271/bbb.66.1479.
• [332] Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. J Med Chem. 2011 Jan 13;54(1):302-11. doi: 10.1021/jm101163m. Epub 2010 Dec 3.
• [333] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [334] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [335] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [336] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [337] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [338] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [339] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [340] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [341] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.